Modeling of Textures to Predict Immune Cell Status and Survival of Brain Tumour Patients

被引:1
|
作者
Chaddad, Ahmad [1 ]
Zhang, Mingli [2 ]
Hassan, Lama [1 ]
Niazi, Tamim [3 ]
机构
[1] Guilin Univ Elect Technol, Sch Artificial Intelligence, Guilin, Guangxi, Peoples R China
[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[3] McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada
关键词
Biomarkers; CNN; Immunotherapy; Radiomics; Survival; GLIOBLASTOMA; LANDSCAPE;
D O I
10.1109/ISBI48211.2021.9434053
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Radiomics has shown a capability for different types of cancers such as glioma to predict the clinical outcome. It can have a non-invasive means of evaluating the immunotherapy response prior to treatment. However, the use of deep convolutional neural networks (CNNs)-based radiomics requires large training image sets. To avoid this problem, we investigate a new imaging features that model distribution with a Gaussian mixture model (GMM) of learned 3D CNN features. Using these deep radiomic features (DRFs), we aim to predict the immune marker status (low versus high) and overall survival for glioma patients. We extract the DRFs by aggregating the activation maps of a pre-trained 3D-CNN within labeled tumor regions of MRI scans that corresponded immune markers of 151 patients. Our experiments are performed to assess the relationship between the proposed DRFs, three immune cell markers (Macrophage M1, Neutrophils and T Cells Follicular Ik!per), and measure their association with overall survival. Using the random forest (RF) model, DRFs was able to predict the immune marker status with area under the ROC curve (AUC) of 78.67, 83.93 and 75.67% for Macrophage M1, Neutrophils and T Cells Follicular Helper, respectively. Combined the immune markers with DRFs and clinical variables, KaplanMeier estimator and Log-rank test achieved the most significant difference between predicted groups of patients (short-term versus long-term survival) with p =4.31 x10(-7) compared to p = 0.03 for Immune cell markers, p = 0.07 for clinical variables, and p =1.45 x10(-5) for DRFs. Our findings indicate that the proposed features (DRFs) used in RF models may significantly consider prognosticating patients with brain tumour prior to surgery through regularly acquired imaging data.
引用
收藏
页码:1067 / 1071
页数:5
相关论文
共 50 条
  • [1] Survival of brain tumour patients with epilepsy
    Mastall, Maximilian
    Wolpert, Fabian
    Gramatzki, Dorothee
    Imbach, Lukas
    Becker, Denise
    Schmick, Anton
    Hertler, Caroline
    Roth, Patrick
    Weller, Michael
    Wirsching, Hans-Georg
    BRAIN, 2021, 144 : 3322 - 3327
  • [2] Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia
    Craig, Stephanie G.
    Humphries, Matthew P.
    Alderdice, Matthew
    Bingham, Victoria
    Richman, Susan D.
    Loughrey, Maurice B.
    Coleman, Helen G.
    Viratham-Pulsawatdi, Amelie
    McCombe, Kris
    Murray, Graeme I.
    Blake, Andrew
    Domingo, Enric
    Robineau, James
    Brown, Louise
    Fisher, David
    Seymour, Matthew T.
    Quirke, Phil
    Bankhead, Peter
    McQuaid, Stephen
    Lawler, Mark
    McArt, Darragh G.
    Maughan, Tim S.
    James, Jacqueline A.
    Salto-Tellez, Manuel
    BRITISH JOURNAL OF CANCER, 2020, 123 (08) : 1280 - 1288
  • [3] Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia
    Stephanie G. Craig
    Matthew P. Humphries
    Matthew Alderdice
    Victoria Bingham
    Susan D. Richman
    Maurice B. Loughrey
    Helen G. Coleman
    Amelie Viratham-Pulsawatdi
    Kris McCombe
    Graeme I. Murray
    Andrew Blake
    Enric Domingo
    James Robineau
    Louise Brown
    David Fisher
    Matthew T. Seymour
    Phil Quirke
    Peter Bankhead
    Stephen McQuaid
    Mark Lawler
    Darragh G. McArt
    Tim S. Maughan
    Jacqueline A. James
    Manuel Salto-Tellez
    British Journal of Cancer, 2020, 123 : 1280 - 1288
  • [4] Immune Status is Prognostic for Poor Survival in Colorectal Cancer Patients and is Associated with Tumour Hypoxia
    Craig, S. G.
    Humphries, M. P.
    Alderdice, M.
    Bingham, V.
    Richman, S. D.
    Loughrey, M. B.
    Coleman, H. G.
    Virathan-Pulsawatdi, A.
    McCombe, K.
    Murray, G. I.
    Blake, A.
    Domingo, E.
    Robineau, J.
    Brown, L.
    Fisher, D.
    Seymour, M. T.
    Quirke, P.
    Bankhead, P.
    McQuaid, S.
    Lawler, M.
    McArt, D. G.
    Maughan, T. S.
    James, J. A.
    Salto-Tellez, M.
    JOURNAL OF PATHOLOGY, 2020, 250 : 17 - 17
  • [5] Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis
    Liu Zhenjiang
    Rao, Martin
    Luo, Xiaohua
    Sandberg, Elisabeth
    Bartek, Jiri, Jr.
    Schoutrop, Esther
    von Landenberg, Anna
    Meng, Qingda
    Valentini, Davide
    Poiret, Thomas
    Sinclair, Georges
    Peredo, Inti-Harvey
    Dodooa, Ernest
    Maeurer, Markus
    EBIOMEDICINE, 2017, 23 : 20 - 24
  • [6] IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients
    Wang, Weili
    Huang, Lei
    Jin, Jian-Yue
    Jolly, Shruti
    Zang, Yong
    Wu, Huanmei
    Yan, Li
    Pi, Wenhu
    Li, Lang
    Mellor, Andrew L.
    Kong, Feng-Ming
    CANCER RESEARCH, 2018, 78 (03) : 809 - 816
  • [7] Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma
    Pflanz, Sandra
    Brookman-Amissah, Sabine
    Roigas, Jan
    Kendel, Friederike
    Hoschke, Bernd
    May, Matthias
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2008, 42 (06): : 507 - 513
  • [8] Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients
    Zhang, Xi
    Weeramange, Chameera Ekanayake
    Hughes, Brett G. M.
    Vasani, Sarju
    Liu, Zhen Yu
    Warkiani, Majid
    Hartel, Gunter
    Ladwa, Rahul
    Thiery, Jean Paul
    Kenny, Liz
    Breik, Omar
    Punyadeera, Chamindie
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2024, 81 (01)
  • [10] Immune phenotypes predict survival in patients with glioblastoma multiforme
    Mostafa, Haouraa
    Pala, Andrej
    Hoegel, Josef
    Hlavac, Michal
    Dietrich, Elvira
    Westhoff, M. Andrew
    Nonnenmacher, Lisa
    Burster, Timo
    Georgieff, Michael
    Wirtz, C. Rainer
    Schneider, E. Marion
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9